Axel Bex
YOU?
Author Swipe
View article: 66Patient perceptions of biomarker testing in kidney cancer (KC) from the international kidney cancer coalition (IKCC) global patient survey (GPS)
66Patient perceptions of biomarker testing in kidney cancer (KC) from the international kidney cancer coalition (IKCC) global patient survey (GPS) Open
Background Recent advancements in kidney cancer research have focused on developing and validating new biomarkers for earlier diagnosis, improved prognosis, and personalized treatment strategies. Patient reception of biomarkers can be comp…
View article: 36International neoadjuvant kidney cancer consortium guidelines on assessing pathological response after neoadjuvant therapy in kidney cancer
36International neoadjuvant kidney cancer consortium guidelines on assessing pathological response after neoadjuvant therapy in kidney cancer Open
Background Despite effective surgery and adjuvant immunotherapy, 1/3 of patients with initially localised renal cell carcinoma (RCC) will go on to develop relapse. Neoadjuvant therapy might improve outcomes for some of these patients; howe…
View article: 11Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis
11Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis Open
Background Understanding how health-related quality of life (HRQOL) concerns vary by disease stage is essential for developing patient-reported outcome measures (PROMs) that reflect the lived experiences of individuals with renal cell carc…
View article: [99mTc]Tc-sestamibi SPECT/CT for the diagnosis of kidney tumours: a multi-centre feasibility study (MULTI-MIBI Study)
[99mTc]Tc-sestamibi SPECT/CT for the diagnosis of kidney tumours: a multi-centre feasibility study (MULTI-MIBI Study) Open
Purpose [ 99m Tc]Tc-sestamibi SPECT/CT (MIBI SPECT/CT) is a promising tool to differentiate benign and malignant renal tumours. We tested feasibility of recruitment to a prospective, multi-centre diagnostic test evaluation study of MIBI SP…
View article: Staging CT chest for cT1a renal masses: Does it change management?
Staging CT chest for cT1a renal masses: Does it change management? Open
Objectives Baseline staging investigations for renal masses invariably include a CT of the chest. However, EAU guidelines have given a weak recommendation that CT chest can be omitted in incidental T1a tumours (≤4 cm) without systemic symp…
View article: 3D-based budding score of renal masses selected for surgery: A novel application of 3D modelling for preoperative prediction of adverse pathological features
3D-based budding score of renal masses selected for surgery: A novel application of 3D modelling for preoperative prediction of adverse pathological features Open
View article: Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma Open
We successfully developed item subsets of the FKSI-23 questionnaire that address the multifaceted impact of localized and metastatic RCC on patients' HRQOL. These two clinical settings required distinct tools for optimal measurement of HRQ…
View article: Reply to Hatice Bolek’s Letter to the Editor re: Hilin Yildirim, Katja K.H. Aben, Maarten J. Bijlsma, et al. A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era. Eur Urol Oncol 2025;8:623–31
Reply to Hatice Bolek’s Letter to the Editor re: Hilin Yildirim, Katja K.H. Aben, Maarten J. Bijlsma, et al. A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era. Eur Urol Oncol 2025;8:623–31 Open
View article: Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma—An Observational Prospective Multicentre Diagnostic Test Cohort Study
Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma—An Observational Prospective Multicentre Diagnostic Test Cohort Study Open
GAGome score had very high sensitivity to ccRCC recurrence, resulting in a negative predictive value of 97%. External validation foreseen in the study design aims to confirm its utility to personalise follow-up for M0 ccRCC patients.
View article: Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma
Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma Open
View article: Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials
Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials Open
View article: Sentinel lymph node staging in urological cancer surgery: advances in imaging, intra‐operative detection and translational research
Sentinel lymph node staging in urological cancer surgery: advances in imaging, intra‐operative detection and translational research Open
Objectives To review the clinical utility, outcome and possible future applications of sentinel lymph node biopsy (SLNB) in penile cancer (PeC), bladder cancer (BCa), prostate cancer (PCa), testicular cancer (TCa) and renal cell carcinoma …
View article: Natural history of treated and untreated renal oncocytoma: a systematic review and meta‐analysis
Natural history of treated and untreated renal oncocytoma: a systematic review and meta‐analysis Open
Introduction Current guidelines recommend active surveillance, surgery, and ablation all as acceptable management strategies for renal oncocytoma, but there is growing concern about overtreatment. Our aim was to report the natural history …
View article: Quality Indicators for Renal Cancer Care: A Systematic Review
Quality Indicators for Renal Cancer Care: A Systematic Review Open
Our review found a relative lack of evidence on QIs for RCC, as well as heterogeneity in their development strategy, definition, reporting, and the included domains of the RCC care pathway. Further efforts are needed to reach consensus on …
View article: An International Delphi Consensus About Tumor Rupture During Robotic Partial Nephrectomy (Researching UnPredictable TUmor RupturE during Robotic Partial Nephrectomy—The RUPTURE Project)
An International Delphi Consensus About Tumor Rupture During Robotic Partial Nephrectomy (Researching UnPredictable TUmor RupturE during Robotic Partial Nephrectomy—The RUPTURE Project) Open
This research looks at tumor rupture during robotic kidney surgery, which can happen but is rare. The study involved a panel of experts who discussed finding a consensus on when it is more likely to occur and how to manage it effectively t…
View article: A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era
A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era Open
View article: Caval thrombectomy a urological leap into the unknown – a call for action
Caval thrombectomy a urological leap into the unknown – a call for action Open
View article: A modified Delphi consensus statement on the role of biopsy in small renal masses
A modified Delphi consensus statement on the role of biopsy in small renal masses Open
Objective To understand the variable utilisation of diagnostic biopsy for small renal masses (SRM) across the urology community, we worked with expert clinicians and patients to produce a consensus statement on the role of biopsy and to id…
View article: Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinoma
Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinoma Open
Background Localised renal cell carcinoma (RCC) is usually treated surgically, with post‐operative imaging‐based surveillance to monitor for recurrence. However, surveillance practices vary widely, and patients often lack a clear understan…
View article: Is Frequent Imaging Necessary? Impact of Computed Tomography During Follow-up After Surgical Treatment for Nonmetastatic Renal Cell Carcinoma: A Systematic Review
Is Frequent Imaging Necessary? Impact of Computed Tomography During Follow-up After Surgical Treatment for Nonmetastatic Renal Cell Carcinoma: A Systematic Review Open
In this review, we assessed radiological follow-up schedules for patients after surgery for kidney cancer and compared these with the follow-up schedules recommended by the European Association of Urology guidelines. We found that most stu…
View article: 68 Integrative biomarkers analysis from the phase 3 CheckMate 914 trial of nivolumab plus ipilimumab or nivolumab versus placebo for adjuvant clear cell renal cell carcinoma (ccRCC)
68 Integrative biomarkers analysis from the phase 3 CheckMate 914 trial of nivolumab plus ipilimumab or nivolumab versus placebo for adjuvant clear cell renal cell carcinoma (ccRCC) Open
View article: O03 A nationwide real-world evaluation of cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma in the IO era
O03 A nationwide real-world evaluation of cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma in the IO era Open
View article: Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report Open
View article: A National Study of the Rate of Benign Pathology After Partial Nephrectomy for T1 Renal Cell Carcinoma: Should We Be Satisfied?
A National Study of the Rate of Benign Pathology After Partial Nephrectomy for T1 Renal Cell Carcinoma: Should We Be Satisfied? Open
Objectives: To determine the rate of benign pathology in cT1 tumors following partial nephrectomy in the Netherlands, thereby evaluating the rate of overtreatment. Methods: Data were collected from a nationwide database containing histopat…
View article: PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor–based First-line Therapy in Metastatic Renal Cell Carcinoma Patients
PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor–based First-line Therapy in Metastatic Renal Cell Carcinoma Patients Open
A maximum of 700 patients with synchronous mRCC and absence of progression at metastatic sites following at least 6 mo of standard first-line ICI combination therapy will be assigned randomly to receive local treatment of the primary tumou…
View article: Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions
Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions Open
View article: Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review
Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review Open
Renal cell carcinoma (RCC) is a very rare type of renal cancer in children and young adults. When metastasized or recurrent, no standards of care are available, and outcome is still poor. The tyrosine kinase inhibitor axitinib is approved …
View article: Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial Open
PURPOSE CheckMate 914 is a two-part, randomized phase III trial evaluating adjuvant nivolumab plus ipilimumab (part A) or adjuvant nivolumab monotherapy (part B) versus placebo in mutually exclusive populations of patients with localized r…
View article: Identifying the facilitators and barriers to implementation of renal tumour biopsy in the diagnostic pathway for small renal masses
Identifying the facilitators and barriers to implementation of renal tumour biopsy in the diagnostic pathway for small renal masses Open
Objectives To understand the facilitators and barriers to the implementation of renal tumour biopsy (RTB) in the diagnostic pathway for renal tumours in England. Patients and Methods Participants consisted of patients who had a renal tumou…
View article: The impact of the COVID-19 pandemic on renal cancer care
The impact of the COVID-19 pandemic on renal cancer care Open